Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
NCT00079118Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and irinotecan in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Objective Response Rate up to 5 years. Started Apr 2004; status: completed.
02
Drugs
docetaxelirinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00079118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079118.